X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership aims to tech transfer and manufacture GS-100, a recombinant AAV9 vector and a suspension process AAV NGLY1 gene therapy for Phase I/II/III clinical trial material for the treatment of NGLY1 Deficiency.
Lead Product(s): GS-100
Therapeutic Area: Genetic Disease Product Name: GS-100
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Grace Science
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 25, 2024
Details:
Armatus will leverage Andelyn's extensive experience in adeno-associated virus (AAV) production and its proprietary suspension platform for its gene therapy treatment for Charcot-Marie-Tooth Type 1A (CMT1A).
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Armatus Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 15, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
